Managing Graves' Disease on Tapering Neomercazole — What Else To Do

1. Monitor for Remission vs. Relapse

• 73% of TRAb-negative patients achieve remission vs. only 28% of TRAb-positive patients after 12 months of ATD therapy
• If TRAb became negative and ATD is stopped: relapse rate ~41%
• If TRAb remains positive at stop: relapse rate ~92%
• A recently proposed algorithm (Azizi et al., 2024, J Clin Endocrinol Metab) recommends: check TRAb at 18 months — if undetectable, consider discontinuation; if still positive, extend treatment to 5 years with biannual TSH/fT4 monitoring

2. Assess Remission Predictors Before Stopping

• Male sex: +1 point
• Age >50 yrs: +1 point
• fT4 >17 pmol/L: +3 points
• T3 >120 ng/dL: +1 point
• TSH <1 mU/L: +1 point
• TRAb >1.75 U/mL: +3 points
• Goiter: +2 points
• Short treatment duration: +6 points

3. Current Lab Monitoring Protocol

• TSH + fT4 + fT3 every 4–6 weeks when adjusting dose, then every 2–3 months once stable on maintenance
• Note: TSH can remain suppressed for months even when fT4 normalises — also check fT3 (T3 thyrotoxicosis possible)
• Before and during ATD therapy: Baseline CBC with differential + LFTs; repeat if symptoms suggest agranulocytosis (sore throat, fever) or hepatotoxicity

4. Watch for Thyroid Eye Disease (TED)

• Examine eyes at every visit (proptosis, lid lag, periorbital oedema, diplopia, visual acuity)
• Smoking is an independent risk factor for relapse and worsens TED — counsel smoking cessation
• If ophthalmopathy present: refer ophthalmology; avoid radioiodine (worsens TED)

5. Screen for Associated Autoimmune Conditions

• Type 1 diabetes mellitus
• Addison's disease
• Vitiligo, alopecia areata
• Pernicious anaemia / B12 deficiency

6. Tapering Strategy — Recent Evidence (2025)

• Final maintenance dose before stopping predicts relapse:
  • 2.5 mg/day: 13.8% relapse at 1 year
  • 1.25 mg/day: 7.1% relapse
  • <1.25 mg/day: only 2.6% relapse
• Tapering to the lowest possible dose before stopping significantly reduces relapse risk

7. Discuss Definitive Therapy Options If TRAb Remains Elevated

Summary Checklist for Your Patient

• Check TRAb — most important prognostic step
• TSH + fT4 + fT3 — monitor every 2–3 months
• CBC + LFTs — if any fever/sore throat or jaundice
• Eye exam — Graves ophthalmopathy screen
• Assess relapse risk score — goiter volume + TRAb level
• Taper to lowest possible dose (<1.25 mg every other day) before stopping
• Counsel on smoking cessation (independent relapse risk factor)
• USG surveillance — for any new nodules (malignancy risk)
• Discuss definitive therapy (RAI or surgery) if TRAb remains positive or relapse occurs

Graves' Ophthalmopathy — Timeline & What to Expect Now

The Clinical Picture

• More severe overall GO
• More active inflammatory phase
• Male sex predominance (your patient fits — young male)
• Higher risk of the uninvolved or less-affected eye progressing to match the worse eye

The Rundle Curve — Natural History Timeline

Severity
    |          ← Active Phase →        ← Inactive/Plateau →
    |         /‾‾‾‾‾‾‾‾‾‾‾‾‾‾\___________________________
    |        /                                             \___
    |_______/                                                  
    0     3-6mo          12-18mo           24mo+

What Will and Won't Resolve Spontaneously?

Immediate Action Points for Your Patient

• Spontaneous orbital pain
• Pain on eye movement
• Eyelid erythema
• Conjunctival injection
• Chemosis
• Swollen caruncle/plica
• Eyelid edema/swelling

• Mild: lid retraction, mild proptosis, no diplopia → observe + supportive (lubricants, selenium)
• Moderate-to-severe: CAS ≥3 + significant proptosis/diplopia/soft tissue → IV methylprednisolone (EUGOGO 2021 guideline first-line)
• Sight-threatening: compressive optic neuropathy, corneal breakdown → emergency decompression

• Selenium 200 mcg/day × 6 months (EUGOGO 2021 recommendation for mild, active GO)
• Shown to improve mild GO and quality of life, delay progression

• Thyroid dysfunction (both hypo- and hyperthyroidism) worsens GO
• This is why tapering neomercazole must be careful and well-monitored

• Smoking doubles GO risk, worsens severity, and nearly abolishes response to RAI
• Most important modifiable risk factor

• Asymmetric/unilateral GO must be referred to a tertiary GO centre
• Rule out other orbital pathology (orbital pseudotumor, lymphoma, cavernous sinus disease) — unilateral proptosis has a broader differential
• Baseline Hertel exophthalmometry, visual acuity, colour vision, fundoscopy

• RAI is contraindicated or should be used with IV steroid cover in moderate-to-severe GO — it can significantly worsen eye disease

Summary

The "staring" bilateral look may have been lid retraction from thyrotoxicosis (sympathetic overdrive), which often resolves with euthyroid control. But now having one eye more affected — that is asymmetric active Graves' orbitopathy and warrants immediate ophthalmology referral and CAS assessment. Active GO takes 18–24 months to burn out naturally, and residual changes (proptosis, fibrosis) never fully reverse. Treat actively now — the window for immunosuppressive efficacy is within the active phase.